Abstract:Purpose To investigate the influence of phenylephrine and tropicamide on anterior segment biometry with ultralong scan depth optical coherence tomography (UL-OCT) during accommodation. Methods In this study, 20 left eyes of healthy volunteers with a mean ± standard deviation age of 31.05 ± 5.84 years and a mean refraction of −1.16 ± 1.11 diopters (range 0∼−3.0 D) were imaged using UL-OCT after instillation of artificial tears, phenylephrine, and tropicamide in three follow-up trials, respectively. At each follow-up trial, two repeated measurements were performed at states of relax and 5D accommodative stimulation. The dimensional parameters included central corneal thickness (CCT), anterior chamber depth (ACD), pupil diameter (PD), lens thickness (LT), and horizontal radii of the lens anterior and posterior surface curvatures (LAC and LPC). Results Tropicamide led to larger pupil, deeper ACD, thinner LT, and flatter crystalline lens surface (P < 0.05). Phenylephrine induced an increase in PD (P < 0.05), while no significant changes were seen in ACD, LT, LAC, and LPC (P > 0.05). CCT did not change after both phenylephrine and tropicamide instillation in this study (P > 0.05). Tropicamide induced the loss of accommodation and phenylephrine achieved pupil dilation without affecting the accommodation. PD, ACD decreased, LT increased significantly and the anterior and posterior surface of the lens in a 6.294 mm of diameter optical zone became steeper during accommodation after administration of phenylephrine (P < 0.05). Conclusion The anterior segment physiology changed after tropicamide instillation. Besides, tropicamide induced the loss of accommodation and phenylephrine preserved the accommodation with a larger pupil. And, the anterior and posterior surface of lens in a 6.294 mm of diameter optical zone became steeper during the accommodation.

Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion

Author Correction: Synergistic Effects of Defocus-Incorporated Multiple Segments and Atropine in Slowing the Progression of Myopia

Anterior Segment Biometry with Phenylephrine and Tropicamide During Accommodation Imaged with Ultralong Scan Depth Optical Coherence Tomography

Increased Choroidal Blood Perfusion Can Inhibit Form Deprivation Myopia in Guinea Pigs

Study design and immediate results of combined opto-pharmacological treatment of progressive myopia in children

The potential of brimonidine for myopia treatment: Targeting MMP-2 to regulate choroidal thickness and control eye growth

Brimonidine as a possible treatment for myopia

Intraocular Pressure-Lowering Efficacy and Safety of Bimatoprost 0.03% Therapy for Primary Open-Angle Glaucoma and Ocular Hypertension Patients in China.

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]

Enhancement of therapeutic efficacy of Brinzolamide for Glaucoma by nanocrystallization and tyloxapol addition

Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy

Micro-interaction of montmorillonite-loaded nanoparticles with mucin promotes retention of betaxolol hydrochloride on the ocular surface and the tear film microenvironment

Lowering Intraocular Pressure: A Potential Approach for Controlling High Myopia Progression

Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2-year multicenter randomized controlled trial

Topical Atropine in the Control of Myopia

Efficacy and Safety of Low Dose Atropine 0.01% in Slowing of Progression of Myopia

Α-Adrenergic Agonist Brimonidine Control of Experimentally Induced Myopia in Guinea Pigs: A Pilot Study.

Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children

[Long-term effect of topically applied isopropyl unoprostone on microcirculation in the choroid-retina].

Current and emerging pharmaceutical interventions for myopia